102 related articles for article (PubMed ID: 3512115)
1. Phase I study of cyclohexylamine and lysine salt of mafosfamide.
Abele R; Aapro MS; Haefliger JM; Alberto P
Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115
[TBL] [Abstract][Full Text] [Related]
2. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
4. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
5. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
Bremner DN; McCormick JS; Thomson JW
Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
[No Abstract] [Full Text] [Related]
7. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
8. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
[No Abstract] [Full Text] [Related]
9. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
10. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.
Eder JP; Elias AD; Ayash L; Wheeler CA; Shea TC; Schnipper LE; Frei E; Antman KH
Cancer Chemother Pharmacol; 1991; 29(1):61-5. PubMed ID: 1742850
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and early clinical trial with mafosfamide as immune modulator.
Klein HO; Kreysch HG; Coerper C; Voigt P; Ruff I
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):627-40. PubMed ID: 3325719
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
14. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
Davila E; Klein L; Vogel CL; Johnson R; Ostroy F; Browning S; Gorowski E; Furner RL; Presant CA
J Clin Oncol; 1985 Jan; 3(1):121-7. PubMed ID: 3965629
[TBL] [Abstract][Full Text] [Related]
16. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure.
Creaven PJ; Cohen MH; Selawry OS; Tejada F; Broder LE
Cancer Chemother Rep; 1975; 59(5):1001-6. PubMed ID: 128411
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
[TBL] [Abstract][Full Text] [Related]
20. Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
Pannier D; Adenis A; Bogart E; Dansin E; Clisant-Delaine S; Decoupigny E; Lesoin A; Amela E; Ducornet S; Meurant JP; Le Deley MC; Penel N
BMC Cancer; 2018 Jul; 18(1):775. PubMed ID: 30064401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]